7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-oxo-3H-pyrrolo[2,3-d]pyrimidine-5-carboximidamide;hydrochloride

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 吡咯并嘧啶核苷和核苷酸
• 英文名称: 7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-oxo-3H-pyrrolo[2,3-d]pyrimidine-5-carboximidamide;hydrochloride
• 化学式: C12H16ClN5O5
• 分子量: 345.74
• InChiKey: ZXJWWJSAZRMIOP-CCUUNMJDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.96
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  166
• 氢给体数：
  7
• 氢受体数：
  6

文献信息

• Pyrrolo[2,3-d]pyrimidine nucleoside analogs
  申请人：——

  公开号：US20020035077A1

  公开（公告）日：2002-03-21

  Compositions and methods for pyrrolo[2,3-d]pyrimidine nucleoside analogs having substituents at the C4′ and C5′ positions of the ribofuranose moiety are presented. Contemplated compositions exhibit, among other things, anti-cancer and immunomodulating effects at reduced cytotoxicity.

  本发明提供了在核糖苷骨架的C4'和C5'位置具有取代基的吡咯[2,3-d]嘧啶核苷类似物的组合物和方法。考虑到的组合物在减少细胞毒性的情况下表现出抗癌和免疫调节等效果。
• PYRROLO(2,3-D)PYRIMIDINE NUCLEOSIDE ANALOGS
  申请人：Ribapharm, Inc.

  公开号：EP1363581A2

  公开（公告）日：2003-11-26
• Nucleoside vaccine adjuvants
  申请人：——

  公开号：US20040191214A1

  公开（公告）日：2004-09-30

  Contemplated methods and compositions include a pharmacological composition comprising an antigen and a nucleoside adjuvant that modulates the balance between Type 1 response and Type 2 response in a lymphocyte, wherein the nucleoside is not an 8-substituted guanine nucleoside. In preferred aspects, contemplated adjuvants stimulate Type 1 response and thereby increase a T-cell response, while contemplated adjuvants may also stimulate a Type 2 response and thereby increase a B-cell response. Preferred adjuvants may further comprise a CpG-dinucleotide and/or a CpG-containing oligonucleotide in a synergistic amount.
• US6831069B2
  申请人：——

  公开号：US6831069B2

  公开（公告）日：2004-12-14
• [EN] PYRROLO[2,3-D]PYRIMIDINE NUCLEOSIDE ANALOGS<br/>[FR] ANALOGUES DE PYRROLO[2,3-D]PYRIMIDINE NUCLEOSIDE
  申请人：RIBAPHARM INC

  公开号：WO2002100354A2

  公开（公告）日：2002-12-19

  Compositions and methods for pyrrolo[2,3-d]pyrimidine nucleoside analogs having substituents at the C4' and C5' positions of the ribofuranose moiety are presented. Contemplated compositions exhibit, among other things, anti-cancer and immunomodulating effects at reduced cytotoxicity.